Secondary analysis shows no link between neuromuscular stimulation duration and motor outcomes in stroke patients, indicating individualized treatment is essential.
The primary objective was to determine the association between electromyography-triggered neuromuscular stimulation (E-nMES) treatment duration and: (a) change in paretic upper extremity (UE) motor impairment; and (b) change in UE functional outcomes. This was a secondary analysis of multicenter, randomized, controlled trial in which E-nMES was applied to 41 participants' paretic UE wrist and finger extensors. The prescribed dose was two, 40-minute sessions per day, occurring 5 days/week, over an 8-week period. E-nMES duration was recorded in minutes by the device. The Fugl-Meyer Upper extremity assessment (FMA) and Arm Motor Ability Test (AMAT) were administered before and one week after intervention completion. Duration of use over the intervention period was 2346.7 + 987.9 min (range = 173 - 3773 min). FM and AMAT scores increased significantly from baseline to end of intervention (FM {Z = -4.58, p < 0.001}; AMAT {Z = -4.41, p < 0.001}). However, no association was found between total duration of E-nMES use and changes at end of intervention (FM {ρ = -0.072; p = 0.65}; AMAT {ρ = 0.079; p = 0.62}). Electrical stimulation duration does not significantly affect movement outcomes, highlighting the need for prioritizing individualized treatment approaches over standardizing stimulation dose.
No takes yet. Share an insight, caveat, or question.
Page et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: